The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness

Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors

(2016) Yi Du et al.   NATURE MEDICINE

Targeting a Cryptic Allosteric Site for Selective Inhibition of the Oncogenic Protein Tyrosine Phosphatase Shp2

(2015) Cynthia M. Chio et al.   BIOCHEMISTRY

Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer

(2015) Grace O. Silva et al.   BREAST CANCER RESEARCH AND TREATMENT

An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis

(2015) Smita Matkar et al.   CANCER CELL

Anthracyclines potentiate anti-tumor immunity: A new opportunity for chemoimmunotherapy

(2015) Zhigang Zhang et al.   CANCER LETTERS

Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling

(2015) A. Hultberg et al.   CANCER RESEARCH

Small-Molecule Stabilization of the 14-3-3/Gab2 Protein-Protein Interaction (PPI) Interface

(2015) David Bier et al.   ChemMedChem

Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts

(2015) M. Bieniasz et al.   CLINICAL CANCER RESEARCH

Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice

(2015) L. Lan et al.   EMBO JOURNAL

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

(2015) Sara M. Tolaney et al.   INVESTIGATIONAL NEW DRUGS

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

(2015) Sara A Hurvitz et al.   LANCET ONCOLOGY

Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition

(2015) Juan Li et al.   MOLECULAR AND CELLULAR BIOLOGY

Better Together: Targeted Combination Therapies in Breast Cancer

(2015) Elisa Zanardi et al.   SEMINARS IN ONCOLOGY

Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis

(2015) Severa Bunda et al.   Nature Communications

HOXB7 Is an ER  Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance

(2015) K. Jin et al.   Cancer Discovery

Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis

(2015) Sébastien Tabariès et al.   Oncotarget

Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development

(2015) Rong Deng et al.   Oncotarget

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains

(2015) Timothy J. Stuhlmiller et al.   Cell Reports

Interaction of CDCP1 with HER2 Enhances HER2-Driven Tumorigenesis and Promotes Trastuzumab Resistance in Breast Cancer

(2015) Abdullah Alajati et al.   Cell Reports

Novel Inhibitors Induce Large Conformational Changes of GAB1 Pleckstrin Homology Domain and Kill Breast Cancer Cells

(2015) Lu Chen et al.   PLoS Computational Biology

Targeting Protein-Tyrosine Phosphatases in Breast Cancer

(2015)   Oncotarget

The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer

(2015) Saori Fujiwara et al.   Oncotarget

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer

(2015) Siti Norasikin Mohd Nafi et al.   Oncotarget

Ron Receptor Tyrosine Kinase Activation Confers Resistance to Tamoxifen in Breast Cancer Cell Lines

(2015) Rebecca J. McClaine et al.   NEOPLASIA

Loss of Estrogen-Regulated microRNA Expression Increases HER2 Signaling and Is Prognostic of Poor Outcome in Luminal Breast Cancer

(2014) S. T. Bailey et al.   CANCER RESEARCH

AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs

(2014) C. Wilson et al.   CANCER RESEARCH

Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab

(2014) L. Castagnoli et al.   CANCER RESEARCH

Overexpression of MERTK Receptor Tyrosine Kinase in Epithelial Cancer Cells Drives Efferocytosis in a Gain-of-Function Capacity

(2014) Khanh-Quynh N. Nguyen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor–positive breast cancer

(2014) Luis J. Schwarz et al.   JOURNAL OF CLINICAL INVESTIGATION

Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution

(2014) Jamie C. Stanford et al.   JOURNAL OF CLINICAL INVESTIGATION

A phosphotyrosine switch determines the antitumor activity of ERβ

(2014) Bin Yuan et al.   JOURNAL OF CLINICAL INVESTIGATION

Axl receptor tyrosine kinase expression in breast cancer

(2014) Timothy M D'Alfonso et al.   JOURNAL OF CLINICAL PATHOLOGY

Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy

(2014) Josep Lluís Parra-Palau et al.   JNCI-Journal of the National Cancer Institute

Axl Phosphorylates Elmo Scaffold Proteins To Promote Rac Activation and Cell Invasion

(2014) Afnan Abu-Thuraia et al.   MOLECULAR AND CELLULAR BIOLOGY

Targeting the disordered C terminus of PTP1B with an allosteric inhibitor

(2014) Navasona Krishnan et al.   Nature Chemical Biology

The ShcA adaptor activates AKT signaling to potentiate breast tumor angiogenesis by stimulating VEGF mRNA translation in a 4E-BP-dependent manner

(2014) Y K Im et al.   ONCOGENE

Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy

(2014) D Elias et al.   ONCOGENE

The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering MBD4-Dependent DNA Methylation Reprogramming

(2014) Stéphanie Cunha et al.   Cell Reports

The Prognostic Ease and Difficulty of Invasive Breast Carcinoma

(2014) Ali Tofigh et al.   Cell Reports

HER4 selectively coregulates estrogen stimulated genes associated with breast tumor cell proliferation

(2013) Wen Han et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Mammary Tumor Formation and Metastasis Evoked by a HER2 Splice Variant

(2013) A. Alajati et al.   CANCER RESEARCH

TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase

(2013) X. Wang et al.   CANCER RESEARCH

Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway

(2013) D. R. Croucher et al.   CANCER RESEARCH

The ShcA PTB Domain Functions as a Biological Sensor of Phosphotyrosine Signaling during Breast Cancer Progression

(2013) R. Ahn et al.   CANCER RESEARCH

Trastuzumab Emtansine: A Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer

(2013) I. Krop et al.   CLINICAL CANCER RESEARCH

Distinct Phosphotyrosine-dependent Functions of the ShcA Adaptor Protein Are Required for Transforming Growth Factor β (TGFβ)-induced Breast Cancer Cell Migration, Invasion, and Metastasis

(2013) Jason J. Northey et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens

(2013) Meghan M. Morrison et al.   JOURNAL OF CLINICAL INVESTIGATION

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes

(2013) Brian D Lehmann et al.   JOURNAL OF PATHOLOGY

Gab2 Phosphorylation by RSK Inhibits Shp2 Recruitment and Cell Motility

(2013) X. Zhang et al.   MOLECULAR AND CELLULAR BIOLOGY

MET and ERBB2 Are Coexpressed in ERBB2+ Breast Cancer and Contribute to Innate Resistance

(2013) A. K. Paulson et al.   MOLECULAR CANCER RESEARCH

Temporal regulation of EGF signalling networks by the scaffold protein Shc1

(2013) Yong Zheng et al.   NATURE

Luminal breast cancer: from biology to treatment

(2013) Michail Ignatiadis et al.   Nature Reviews Clinical Oncology

Interaction with Shc prevents aberrant Erk activation in the absence of extracellular stimuli

(2013) Kin Man Suen et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling

(2013) I S Harris et al.   ONCOGENE

AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells

(2013) M K Asiedu et al.   ONCOGENE

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

(2013) A. B. Hanker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer

(2013) J. F. Knight et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells

(2013) A. S. Meyer et al.   Science Signaling

Molecular Mechanisms of SH2- and PTB-Domain-Containing Proteins in Receptor Tyrosine Kinase Signaling

(2013) M. J. Wagner et al.   Cold Spring Harbor Perspectives in Biology

Inhibition of Ron Kinase Blocks Conversion of Micrometastases to Overt Metastases by Boosting Antitumor Immunity

(2013) H. Eyob et al.   Cancer Discovery

Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer

(2012) Veronique M. Neumeister et al.   BREAST CANCER RESEARCH AND TREATMENT

Molecular insights on basal-like breast cancer

(2012) Mev Dominguez Valentin et al.   BREAST CANCER RESEARCH AND TREATMENT

Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

(2012) C. Garcia-Garcia et al.   CLINICAL CANCER RESEARCH

Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy

(2012) Daniela Gallo et al.   CURRENT PHARMACEUTICAL DESIGN

Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer

(2012) T. Hansmann et al.   HUMAN MOLECULAR GENETICS

Met receptor tyrosine kinase signals through a cortactin–Gab1 scaffold complex, to mediate invadopodia

(2012) Charles V. Rajadurai et al.   JOURNAL OF CELL SCIENCE

GAB2--a Scaffolding Protein in Cancer

(2012) S. J. Adams et al.   MOLECULAR CANCER RESEARCH

The Signaling Adaptor Gab1 Regulates Cell Polarity by Acting as a PAR Protein Scaffold

(2012) Ziqiang Yang et al.   MOLECULAR CELL

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop

(2012) Nicola Aceto et al.   NATURE MEDICINE

Functional characterization of cancer-associated Gab1 mutations

(2012) C Ortiz-Padilla et al.   ONCOGENE

The ShcA SH2 domain engages a 14-3-3/PI3′K signaling complex and promotes breast cancer cell survival

(2012) J Ursini-Siegel et al.   ONCOGENE

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

(2012) Ron Bose et al.   Cancer Discovery

Formation of the eIF4F Translation-Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors

(2011) P. Zindy et al.   CANCER RESEARCH

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

(2011) R. Ghosh et al.   CANCER RESEARCH

p95HER2 and Breast Cancer

(2011) J. Arribas et al.   CANCER RESEARCH

A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer

(2011) E. M. Fox et al.   CANCER RESEARCH

Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase

(2011) Tingting Sun et al.   CELL

Global Proteomic Assessment of the Classical Protein-Tyrosine Phosphatome and “Redoxome”

(2011) Robert Karisch et al.   CELL

Function ofERBB4is determined by alternative splicing

(2011) Ville Veikkolainen et al.   CELL CYCLE

A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor-Positive Breast Cancer

(2011) E. L. Mayer et al.   CLINICAL CANCER RESEARCH

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition

(2011) B N Rexer et al.   ONCOGENE

The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium

(2011) J. M. Balko et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling

(2011) V. N. Kristensen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients

(2011) Maurizio Scaltriti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

(2011) A. Chakrabarty et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

(2011) J. T. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PPM1H Is a p27 Phosphatase Implicated in Trastuzumab Resistance

(2011) S. T. Lee-Hoeflich et al.   Cancer Discovery

LYN Is a Mediator of Epithelial-Mesenchymal Transition and a Target of Dasatinib in Breast Cancer

(2010) Y.-L. Choi et al.   CANCER RESEARCH

FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer

(2010) N. Turner et al.   CANCER RESEARCH

Receptor Tyrosine Kinase Signaling Favors a Protumorigenic State in Breast Cancer Cells by Inhibiting the Adaptive Immune Response

(2010) J. Ursini-Siegel et al.   CANCER RESEARCH

Transcriptional Control of the ERBB2 Amplicon by ERR  and PGC-1  Promotes Mammary Gland Tumorigenesis

(2010) G. Deblois et al.   CANCER RESEARCH

Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells

(2010) F. Hochgrafe et al.   CANCER RESEARCH

BRCA1 Basal-like Breast Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells

(2010) Gemma Molyneux et al.   Cell Stem Cell

Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development

(2010) Emmy D.G. Fleuren et al.   INTERNATIONAL JOURNAL OF CANCER

PTP1B: a double agent in metabolism and oncogenesis

(2010) Shu-Chin Yip et al.   TRENDS IN BIOCHEMICAL SCIENCES

Subcellular Localization of the HER4 Intracellular Domain, 4ICD, Identifies Distinct Prognostic Outcomes for Breast Cancer Patients

(2009) Ann D. Thor et al.   AMERICAN JOURNAL OF PATHOLOGY

Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy

(2009) G. Zhuang et al.   CANCER RESEARCH

Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models

(2009) W. Scheuer et al.   CANCER RESEARCH

Crk adaptor protein-induced phosphorylation of Gab1 on tyrosine 307 via Src is important for organization of focal adhesions and enhanced cell migration

(2009) Takuya Watanabe et al.   CELL RESEARCH

Tyrosine phosphorylation: thirty years and counting

(2009) Tony Hunter   CURRENT OPINION IN CELL BIOLOGY

The Ron receptor tyrosine kinase negatively regulates mammary gland branching morphogenesis

(2009) Sara E. Meyer et al.   DEVELOPMENTAL BIOLOGY

Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis

(2009) Jane E. Visvader   GENES & DEVELOPMENT

Identification of Shc Src Homology 2 Domain-Binding Peptoid−Peptide Hybrids

(2009) Won Jun Choi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

(2009) C. Gjerdrum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

(2009) M. G. Ponzo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin

(2008) Azza Ben Hamida et al.   BMC CANCER

A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy

(2008) S. T. Lee-Hoeflich et al.   CANCER RESEARCH

Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein

(2008) Tilman Brummer et al.   EMBO JOURNAL

ShcA signalling is essential for tumour progression in mouse models of human breast cancer

(2008) Josie Ursini-Siegel et al.   EMBO JOURNAL

SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis

(2008) X Zhou et al.   HISTOPATHOLOGY

A Phosphorylation-Dependent Gating Mechanism Controls the SH2 Domain Interactions of the Shc Adaptor Protein

(2008) Roger George et al.   JOURNAL OF MOLECULAR BIOLOGY